|
|
|
| Combination therapy of dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer |
| Alessandro Rizzo ∗, Angela Dalia Ricci , Giovanni Brandi |
Division of Oncology, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italy
∗ Corresponding author.
E-mail address: rizzo.alessandro179@gmail.com (A. Rizzo). |
|
|
|
|
Abstract In the last decade, next-generation sequencing (NGS)-based molecular profiling has shed light on the molecular landscape of biliary tract cancer (BTC), revealing the presence of several potentially actionable mutations [1]. According to ClinicalTrials.gov, there are at least 40 phase I to IV ongoing trials aimed at evaluating the role of targeted treatments in BTC, as monotherapy or in combination with other anticancer agents [2]. Early encouraging results have been observed with therapies targeting IDH mutations, FGFR fusions, HER family and, more recently, BRAF mutations [3].
|
|
|
|
|
|
|
|
|
2021, Vol. 20 
